Home Microbiology Reverse Transcriptase inhibitor Nevirapine (NSC 641530)

research use only

Nevirapine (NSC 641530) Reverse Transcriptase inhibitor

Nevirapine (NSC 641530,NVP), a non-nucleoside reverse transcriptase inhibitor (NNRTI), is used to treat HIV-1 infection and AIDS.

Nevirapine (NSC 641530) Reverse Transcriptase inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 266.3

Purity & Quality Control

Related Products

Signaling Pathway

Reverse Transcriptase Signaling Pathways

Reverse Transcriptase Signaling Pathway

Cell Culture and Working Concentration

Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
CEM-SS cells Function assay Antiviral activity against HIV1 RF in CEM-SS cells assessed as inhibition of virus-induced cytopathic effect by XTT assay, EC50=1.5 nM
human MT4 cells Function assay Antiviral activity against Human immunodeficiency virus 1 subtype C infected in human MT4 cells assessed as reduction in virus induced cytopathicity, EC50=0.00488 μM
human Jurkat E6-1 cells Function assay 2 days Antiviral activity against HIV1 Env-pseudovirus infected in human Jurkat E6-1 cells after 2 days by luciferase assay, IC50=0.04 μM
human C1866 cells Cytotoxicity assay 72 h Cytotoxicity against human C1866 cells after 72 hrs by MTT assay, EC50=0.04943 μM
human MT2 cells Function assay 4 days Antiviral activity against wild type HIV1 3B infected in human MT2 cells assessed as inhibition of p24 antigen production after 4 days by ELISA, EC50=0.053 μM
HeLa cells Function assay Antiviral activity against wild type HIV1 in HeLa cells by MAGI assay, IC50=0.053 μM
293T cells Function assay Inhibition of wild type HIV1 reverse transcriptase in 293T cells, IC50=0.06 μM
MDCK2 cells Function assay 10 μM Inhibition of human MRP2 expressed in MDCK2 cells assessed as increase in intracellular CMF fluorescence at 10 uM by CMFDA assay
Click to View More Cell Line Experimental Data

Mechanism of Action

Targets
Reverse transcriptase [1]

In vitro
In vitro

Nevirapine (NSC 641530) is a non-nucleoside RT inhibitor with a well-characterized inhibitory activity on RT enzymes of retroviral origin. It is also an effective inhibitor of the endogenous RT in murine and human cell lines. This compound itself is an inhibitor of only CYP3A4 at concentrations that are well above those of therapeutic relevance (Ki = 270 mM). [1] Its exposure rescues the differentiation block present in acute myeloid leukemia (AML) cell lines and primary blasts from two AML patients, as indicated by morphological, functional and immunophenotypic assays. [2] As a dipyridodiazepinone, it is a highly specific inhibitor of HIV-1 reverse transcriptase (RT) which exhibits an IC50 = 84 nM in enzyme assays and IC50 = 40nM against HIV-1 replication in cell culture. [3] It alters the cleavage specificity of the RNase H, resulting in Nevirapine-induced stimulation of RNase H activity beyond the increase expected from the change in cleavage specificity. [4]

In Vivo
In vivo

Nevirapine (NSC 641530) is metabolized to 4-CANVP as a major metabolite in all male animals and in the female mouse, dog, and monkey. 3-OHNVP is a major fecal metabolite in all animals except for the male rat. 4-CANVP is a major metabolite along with 12-OHNVP glucuronide in the bile of rats. [5]
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05725252 Completed
Healthy Volunteers
NVP Healthcare
 May 28 2023 Phase 1
NCT05354713 Completed
Healthy Volunteers
NVP Healthcare
 November 5 2022 Phase 1
NCT04926727 Unknown status
Nausea Gravidarum|Vomiting of Pregnancy
Italfarmaco|Opera CRO a TIGERMED Group Company
 October 4 2021 --
NCT02738502 Completed
Maternal-fetal Infection Transmission
ANRS Emerging Infectious Diseases|Institut National de la Santé Et de la Recherche Médicale France
 July 6 2016 Phase 2
NCT02383849 Completed
Low-Birth-Weight Infant|Tuberculosis|HIV
International Maternal Pediatric Adolescent AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
 August 4 2015 --

References
  • https://pubmed.ncbi.nlm.nih.gov/10570031/
  • https://pubmed.ncbi.nlm.nih.gov/12747369/
  • https://pubmed.ncbi.nlm.nih.gov/1371691/
  • https://pubmed.ncbi.nlm.nih.gov/7533167/
  • https://pubmed.ncbi.nlm.nih.gov/10570025/

Chemical Information

Molecular Weight 266.3 Formula

C15H14N4O
CAS No. 129618-40-2 SDF Download SDF
Synonyms NSC 641530,NVP
Smiles CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4

Storage and Stability

Storage (From the date of receipt)

In vitro
Batch:

DMSO : 53 mg/mL ( (199.02 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : Insoluble

Ethanol : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.